Trump’s Pharmaceutical Tariffs: Is This America’s New Drug War?
By Emma Savage ‘27
The Trump Administration has imposed tariffs on imported branded and biosimilar pharmaceutical products. By implementing tariffs on pharmaceuticals and active pharmaceutical ingredients, the administration aims to encourage domestic manufacturing. Additionally, the intention is to recalibrate trade relationships and reshape global supply chains. However, the expansion of these tariffs raises significant concerns in the United States. Most notably, there are concerns about potential cost increases and limitations on patients' access to their medication.
Background
The United States pharmaceutical industry has long relied heavily on an interconnected global supply chain to produce both the ingredients for medications and the finished drug products. Historically and globally, the U.S. has depended on foreign pharmaceutical production to meet its medical needs. While sourcing active pharmaceutical ingredients from other countries has been beneficial, it has also attracted backlash. The COVID-19 pandemic raised crucial questions about national security and access to medicine in life-or-death situations. Compounding the issue, the United States' pharmaceutical trade deficit in 2024 placed a significant burden on the nation's budget, leading to lasting effects. In response to these disruptions, Trump established tariffs on pharmaceutical and medical supplies to encourage onshore production in the U.S. The administration wants to bring drug administration “back home” to the United States of America.
On April 15, 2025, the Commerce Department opened a comprehensive Section 232 investigation into the pharmaceutical industry. The findings of the policy allow the president to justify tariffs as a means to stimulate domestic production and protect national security interests. Trump’s rationale behind these tariffs combines national security, economic, and political considerations. Whether these justifications outweigh the potential concerns will ultimately depend on the patients who will be impacted.
Impact and Justification
American society remains deeply fractured over core issues such as the proper roles of government and market, and the balance between individual responsibility and social security. Most United States citizens support greater government involvement in the healthcare system. However, this notion is unpredictable and stagnant, especially between the two major political parties. In general, Democrats advocate a more decisive government role with coverage and equity, while Republicans favor market-oriented approaches. Supporters of these tariffs may argue that government intervention with tariffs is essential to protect national interests and security. This aligns with the Trump Administration’s primary goals, which include imposing national security and economic fairness in the United States of America.
Dependence on other countries, especially in places like China, poses a national security threat. The COVID-19 pandemic and its handling are excellent examples of the problems that come with reliance on other countries. Initially, it appeared to be a health crisis, but the severity of the pandemic triggered a cascade of effects and led to deglobalization. There was limited engagement among citizens to prevent the virus from spreading, which altered the world's ability to function correctly. Global transport came to a standstill, resulting in significant delays in the export of vital medical supplies essential to supporting national and regional governments and communities in need.
The United States’ reliance on foreign pharmaceutical products profoundly affected the country, leading to substantial consequences. China alone produces a large amount of the country's generic medications, ingredients, and pharmaceuticals. When factories in other countries slowed down, there was a significant ripple effect, leading to a shortage of essential drugs and medications across the United States. Hospitals and pharmacies found themselves overwhelmed with an increasing number of patients while facing a shortage of essential medications. The Trump administration recognized that the drug supply chain in America posed a significant national security concern. As a result, it emphasized the need for the United States to address health emergencies independently, without relying on foreign manufacturers. These tariffs were implemented as a safeguard against future health emergencies and disruptions, ensuring the continued production of critical drugs and safe public health.
Alongside COVID-19, the United States' pharmaceutical trade deficit in 2024 was $139 billion, contributing significantly to the overall goods trade deficit of $1.2 trillion and placing a considerable burden on the nation's economy. During this time, the United States imported over 828,000 metric tons of pharmaceutical products, 7 times the amount in 2000. This caused a large trade deficit and collapsed the pharmaceutical trade balance that had been established. This is a dangerous policy failure that shows how reliance on countries for products not only weakens domestic production capacity but also diverts billions of dollars the country needs. The Trump Administration argues that government intervention is not only justified but also necessary to protect and correct the national economy and restore balance.
On Tuesday, April 15, 2025, the Commerce Department opened a broad Section 232 investigation into generic pharmaceutical imports. Section 232 of the Trade Expansion Act of 1962 gives President Trump the authority to decide whether the United States, relying on imported drugs and pharmaceutical ingredients, poses a threat to the country. This investigation frames the trade deficit as a national security threat that must be addressed with government intervention. The Trump Administration plans to mandate complete supply chain transparency while imposing tariffs on imports to expand domestic production and strengthen FDA enforcement abroad.
Potential Consequences
Tariffs typically cause a range of negative consequences, including supply chain disruptions, which can lead to shortages and price spikes rather than increase security. The point of these tariffs is to enhance national security; however, they may destabilize the global trade networks the country is trying to support. In general, tariffs tend to take a higher proportion of income from the poor than from those with higher incomes. This means that patients who rely on affordable pharmaceuticals and medications will have a harder time maintaining their access to them without a financial burden. This policy may have unintended consequences, resulting in higher medication prices. Patients may experience higher costs for medicine, insurance, and taxes. These medications may now have drastic out-of-pocket costs, making them more challenging for the average household to obtain.
The majority of pharmaceutical products in America are global in origin, meaning many patients' medications are manufactured in other countries or sourced from there. Most of the United States' pharmaceutical ingredients used to create essential medications for patients are imported. Innovative research on the development of drugs and their potential to treat diseases can be negatively affected and slowed. Many diseases and medications that have not been explored require international components. If a company cannot relocate its production to the United States, the supply of ingredients and medications will be affected, potentially limiting patients' access to medicines and leading to shortages. The majority of drug shortages in the United States have been caused by disruptions within U.S. manufacturing sites, indicating that these tariffs could lead to even more shortages. Drug famine and procedural delays interrupt effective patient care and can alter the medications they are able to take. If a patient can no longer afford their medication, they may have to resort to taking out loans, shortening the dosage, or even going without it. This can be a dangerous life-or-death situation when you think of prescriptions such as insulin or epinephrine.
Not only are patients paying more, but companies will also lose money if they are unable to ship their products to the United States. The Budget Lab at Yale University projected that a 25% ad valorem tariff, taxed as a percentage of a product's value rather than a fixed dollar amount, could increase medication costs by an “average of around $600 per year per household in the United States.” Estimates indicate that such tariffs could increase U.S. drug expenditures by approximately $51 billion annually. This adverse effect of policy implementation harms pharmaceutical consumers and the financial stability of companies that sell and transport the products.
These tariffs could offer short-term relief against countries' vulnerabilities; however, they may place long-term strain on the economy and burden patients. We need to ask ourselves: Are tariffs on pharmaceuticals truly the best option for the United States and its citizens?
Emma Savage is a junior majoring in political science.
Sources
Sullivan, S., Grueger, J., Sullivan, P., and Ramsey, S. (2025). The Consequences of Pharmaceutical Tariffs in The United States. Journal of Managed Care & Specialty Pharmacy, vol. 31, no. 6. https://www.jmcp.org/doi/full/10.18553/jmcp.2025.25090
Jordan, A. (2025). U.S. Pharma Tariffs: Impact on Costs, Supply, and Trade. ResearchGate.https://www.researchgate.net/profile/Amy-Jordan-12/publication/392123419_US_PHARMA_TARIFFS_IMPACT_ON_COSTS_SUPPLY_AND_TRADE/links/68357bc8026fee1034fc3d27/US-PHARMA-TARIFFS-IMPACT-ON-COSTS-SUPPLY-AND-TRADE.pdf
Roades, T., Colvill, S., and Mclellan, M. (2025). Pharmaceutical Tariffs: Potential Impacts And The Need For Vulnerability Assessments. Health Affairs Forefront.
Wang, M. (2025). Tariff Conflicts and Entrenched Interests: The Deepening Deadlock of US Healthcare Reform. Health Care Analysis. https://link.springer.com/article/10.1007/s10728-025-00542-1
Bauer, M., Lamprecht, P. (2021). How Tariffs Impact Access to Medicines. Geneva-Network Working Paper. https://www.wita.org/wp-content/uploads/2021/10/2021-how-tariffs-impact-access-to-medicines.pdf
Rechenberg, A. (2025). U.S. Dangerously Reliant on High-Risk Imported Drug Supply. Prosperous America.
https://prosperousamerica.org/u-s-dangerously-reliant-on-high-risk-imported-drug-supply/
